Recent innovations in the management of low-grade gliomas

Shaheryar Hafeez, Robert Cavaliere

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Advancement in the understanding of biologic mechanisms of low-grade glioma pathophysiology has allowed the modern era of patient-specific genetic profiling, molecular biology, and neuroimaging to design new methods of surgery, radiation, and chemotherapy in hopes of preventing malignant transformation and improving outcomes. Recent innovations in the understanding of MGMT promoter methylation, IDH1 and IDH2 mutations, temozolomide chemotherapy, vascular monoclonal antibody treatment, use of radiation therapy, choice of antiepileptic drugs, surgical resection, and neuroimaging of lowgrade gliomas are reviewed.

Original languageEnglish (US)
Pages (from-to)369-380
Number of pages12
JournalCurrent Treatment Options in Neurology
Issue number4
StatePublished - Aug 2012
Externally publishedYes


  • 1p/19q deletion
  • Chemotherapy
  • Clinical trials
  • IDH1 mutation
  • IDH2 mutation
  • Low-grade glioma
  • PCV
  • Prognostic factors
  • Progression-free survival
  • Surgery
  • Survival
  • TMZ
  • Treatment
  • Vaccination

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Recent innovations in the management of low-grade gliomas'. Together they form a unique fingerprint.

Cite this